Supplementary Figure from Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer
التفاصيل البيبلوغرافية
العنوان:
Supplementary Figure from Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer
American Association for Cancer Research (AACR), 2023.
سنة النشر:
2023
الوصف:
Supplementary Figure from Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer
